CliffBio
biologic

Truxima

rituximab-abbs

Loss of exclusivity—loss of exclusivity
CompanyCelltrion →See this company's full patent-cliff portfolio

Drug detail

Brand nameTruxima
Active ingredientrituximab-abbs
Strength100MG/10ML (10MG/ML)
Dosage formInjection
RouteIntravenous
ModalityBiologic
FDA approvalNovember 2018
Marketing statusRx

More from Celltrion

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the loss of exclusivity; estimates are projections, not legal advice.